StockData

Neurogene vs Cartesian Therapeutics

NGNE and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NGNE and RNAC compare

Neurogene is the larger company, worth 2.4 times as much as Cartesian Therapeutics ($466M against $192M).

Neurogene scores higher on the StockData Score (6 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNGNERNAC
Size and price
Market cap$466M$192M
Share price$23.30$6.35
Change, 1 year−12.0%−16.2%
Change, 5 years−77.2%−93.4%
Beta (5Y)2.00–
Employees13175
StockData Score
Total score6 (better)1
Valuation score00
Growth score00
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S–130×
P/B2.1×–
FCF yield−18.8% (better)−40.9%
Growth
Revenue growth, 5Y average–−30.0%
Profitability
Operating margin–−10519%
Net margin–−10284%
FCF margin–−5322%
Return on equity−45.3%–
Financial health
Debt / equity0.00–
Interest coverage−60673.0×–
Current ratio10.64 (better)7.48
Altman Z-score7.26 (better)−4.56
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.5%29.3%
Held by insiders15.9%55.7%
Insider net buying, 12 months−$1.1M−$52.9K (better)
Short interest, % of float33.8%14.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.